|Dr. Mark A. Goldsmith Ph.D.||CEO, Pres & Chairman||1.01M||2.21M||1962|
|Mr. Jack Anders||Chief Financial Officer||462.13k||N/A||1977|
|Ms. Margaret A. Horn J.D.||COO, Gen. Counsel & Sec.||773.03k||1.76M||1963|
|Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.||Pres of R&D||773.03k||N/A||1961|
|Ms. Xiaolin Wang||Exec. VP of Clinical Devel.||582.43k||N/A||1971|
|Dr. Martin D. Burke M.D., Ph.D.||Co-Founder & Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Michael A. Fischbach Ph.D.||Academic Co-Founder & Member of Scientific Advisory Board||N/A||N/A||1981|
|Dr. Kevan M. Shokat Ph.D.||Academic Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. David L. Pompliano Ph.D.||Founding Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Walter Reiher Ph.D.||Chief Information Officer||N/A||N/A||N/A|
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 8; Compensation: 7.